Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions in revenue, and there's still much more growth on the horizon. Over the past 12 months, however, it's been Eli Lilly that has been the far better buy, rising more than 17%, while Novo Nordisk's stock has fallen by over 30%.But investors shouldn't read too much into this performance as Novo Nordisk just posted a solid quarter, and there's plenty of reason to remain bullish on the healthcare stock this year. Here's why the stock may be a no-brainer buy right now.Last week, Novo Nordisk released its year-end results, including how it performed over the last three months of 2024. Net sales for the quarter totaled 85.7 billion Danish kroner ($12 billion) and rose by 30% year over year. Its quarterly profit of 28.2 billion Danish kroner ($3.9 billion) increased by a slightly lower rate of 29%, but it came in comfortably higher than the 26.1 billion Danish kroner ($3.7 billion) that analysts were expecting. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool